Serum Potassium, Mortality, and Kidney Outcomes in the Atherosclerosis Risk in Communities Study

Mayo Clinic Proceedings

Volumn 91, Issue 10, 2016, Pages 1403-1412

  Chen, Yan ^a   Chang, Alex R ^b   McAdams DeMarco, Mara A ^a,c   Inker, Lesley A ^d   Matsushita, Kunihiro ^a   Ballew, Shoshana H ^a   Coresh, Josef ^a,c   Grams, Morgan E ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; POTASSIUM BLOOD LEVEL; RISK ASSESSMENT; SUDDEN CARDIAC DEATH; AGED; BLOOD; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE, CHRONIC; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

ADULT; AGED; DEATH, SUDDEN, CARDIAC; DIURETICS, POTASSIUM SPARING; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; HYPOKALEMIA; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; POTASSIUM; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SODIUM CHLORIDE SYMPORTER INHIBITORS; UNITED STATES;

EID: 84994310917     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.05.018     Document Type: Article

References (52)

1. 1 Lehnhardt, A., Kemper, M.J., Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol 26:3 (2011), 377–384.
2. 2 Giebisch, G., Hebert, S.C., Wang, W.H., New aspects of renal potassium transport. Pflugers Arch 446:3 (2003), 289–297.
3. 3 Wang, H.H., Hung, C.C., Hwang, D.Y., et al. Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease. PLoS One, 8(7), 2013, e67140.
4. 4 Hayes, J., Kalantar-zadeh, K., Lu, J.L., Turban, S., Anderson, J.E., Kovesdy, C.P., Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract 120:1 (2012), c8–c16.
5. 5 Ahmed, A., Zannad, F., Love, T.E., et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 28:11 (2007), 1334–1343.
6. 6 Luo, J., Brunelli, S.M., Jensen, D.E., Yang, A., Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol 11:1 (2016), 90–100.
7. 7 Tannen, R.L., Diuretic-induced hypokalemia. Kidney Int 28:6 (1985), 988–1000.
8. 8 Greenberg, A., Diuretic complications. Am J Med Sci 319:1 (2000), 10–24.
9. 9 Maddirala, S., Khan, A., Vincent, A., Lau, K., Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. Am J Med Sci 336:4 (2008), 330–335.
10. 10 Arrizabalaga, P., Montoliu, J., Martinez vea, A., Andreu, L., Lópezpedret, J., Revert, L., Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone. Proc Eur Dial Transplant Assoc 20 (1983), 572–576.
11. 11 Kovesdy, C.P., Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol 10:11 (2014), 653–662.
12. 12 The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC Investigators. Am J Epidemiol 129:4 (1989), 687–702.
13. 13 National Heart, Lung, and Blood Institute website. The Atherosclerosis Risk in Communities (ARIC) Study (ARIC). http://www.nhlbi.nih.gov/research/resources/obesity/population/aric.htm. Accessed February 12, 2016.
14. 14 National Heart, Lung, and Blood Institute Atherosclerosis Risk in Communities ARIC Study, Operations Manual No. 10: Clinical Chemistry Determinations, 45, 1987, National Heart, Lung, and Blood Institute, Bethesda, MD, 67.
15. 15 Eckfeldt, J.H., Chambless, L.E., Shen, Y.L., Short-term, within-person variability in clinical chemistry test results: experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med 118:5 (1994), 496–500.
16. 16 Coresh, J., Astor, B.C., Mcquillan, G., et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 39:5 (2002), 920–929.
17. 17 Levey, A.S., Stevens, L.A., Schmid, C.H., et al., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 150:9 (2009), 604–612.
18. 18 Willett, W.C., Sampson, L., Browne, M.L., et al. The use of a self-administered questionnaire to assess diet four years in the past. Am J Epidemiol 127:1 (1988), 188–199.
19. 19 Chatterjee, R., Yeh, H.C., Shafi, T., et al. Serum and dietary potassium and risk of incident type 2 diabetes mellitus: the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 170:19 (2010), 1745–1751.
20. 20 White, A.D., Folsom, A.R., Chambless, L.E., et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol 49:2 (1996), 223–233.
21. 21 Chen, L.Y., Sotoodehnia, N., Bůžková, P., et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med 173:1 (2013), 29–35.
22. 22 Soliman, E.Z., Prineas, R.J., Case, L.D., et al. Electrocardiographic and clinical predictors separating atherosclerotic sudden cardiac death from incident coronary heart disease. Heart 97:19 (2011), 1597–1601.
23. 23 Peacock, J.M., Ohira, T., Post, W., Sotoodehnia, N., Rosamond, W., Folsom, A.R., Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 160:3 (2010), 464–470.
24. 24 Olson, K.A., Viera, A.J., Soliman, E.Z., Crow, R.S., Rosamond, W.D., Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study. Eur Heart J 32:24 (2011), 3098–3106.
25. 25 Grams, M.E., Rebholz, C.M., Mcmahon, B., et al. Identification of incident CKD stage 3 in research studies. Am J Kidney Dis 64:2 (2014), 214–221.
26. 26 Rebholz, C.M., Coresh, J., Ballew, S.H., et al. Kidney failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) Study: comparing ascertainment of treated and untreated kidney failure in a cohort study. Am J Kidney Dis 66:2 (2015), 231–239.
27. 27 Fang, J., Madhavan, S., Cohen, H., Alderman, M.H., Serum potassium and cardiovascular mortality. J Gen Intern Med 15:12 (2000), 885–890.
28. 28 Alderman, M.H., Piller, L.B., Ford, C.E., et al. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 59:5 (2012), 926–933.
29. 29 Kovesdy, C.P., Management of hyperkalemia: an update for the internist. Am J Med 128:12 (2015), 1281–1287.
30. 30 Lim, P., Jacob, E., Magnesium deficiency in patients on long-term diuretic therapy for heart failure. Br Med J 3:5827 (1972), 620–622.
31. 31 Wester, P.O., Dyckner, T., Diuretic treatment and magnesium losses. Acta Med Scand Suppl 647 (1981), 145–152.
32. 32 Perez-stable, E., Caralis, P.V., Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J 106:1, Pt 2 (1983), 245–251.
33. 33 Grimm, R.H. Jr., Leon, A.S., Hunninghake, D.B., Lenz, K., Hannan, P., Blackburn, H., Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med 94:1 (1981), 7–11.
34. 34 Bloomgarden, Z.T., Ginsberg-fellner, F., Rayfield, E.J., Bookman, J., Brown, W.V., Elevated hemoglobin A1c and low-density lipoprotein cholesterol levels in thiazide-treated diabetic patients. Am J Med 77:5 (1984), 823–827.
35. 35 Steele, T.H., Oppenheimer, S., Factors affecting urate excretion following diuretic administration in man. Am J Med 47:4 (1969), 564–574.
36. 36 Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. JASA 94:446 (1999), 496–509.
37. 37 Wannamethee, S.G., Lever, A.F., Shaper, A.G., Whincup, P.H., Serum potassium, cigarette smoking, and mortality in middle-aged men. Am J Epidemiol 145:7 (1997), 598–606.
38. 38 Fukui, M., Tanaka, M., Toda, H., et al. Low serum potassium concentration is a predictor of chronic kidney disease. Int J Clin Pract 68:6 (2014), 700–704.
39. 39 Patel, R.B., Tannenbaum, S., Viana-tejedor, A., et al. Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. [published online ahead of print] Eur Heart J Acute Cardiovasc Care, December 29, 2015.
40. 40 Hulting, J., In-hospital ventricular fibrillation and its relation to serum potassium. Acta Med Scand Suppl 647 (1981), 109–116.
41. 41 Solomon, R.J., Cole, A.G., Importance of potassium in patients with acute myocardial infarction. Acta Med Scand Suppl 647 (1981), 87–93.
42. 42 Friedensohn, A., Faibel, H.E., Bairey, O., Goldbourt, U., Schlesinger, Z., Malignant arrhythmias in relation to values of serum potassium in patients with acute myocardial infarction. Int J Cardiol 32:3 (1991), 331–338.
43. 43 Mattsson, N., Sadjadieh, G., Kumarathurai, P., Nielsen, O.W., Køber, L., Sajadieh, A., Ambulatory cardiac arrhythmias in relation to mild hypokalaemia and prognosis in community dwelling middle-aged and elderly subjects. Europace 18:4 (2016), 585–591.
44. 44 Podrid, P.J., Potassium and ventricular arrhythmias. Am J Cardiol 65:10 (1990), 33E–44E discussion 52E.
45. 45 Weisberg, L.S., Management of severe hyperkalemia. Crit Care Med 36:12 (2008), 3246–3251.
46. 46 Menahem, S.A., Perry, G.J., Dowling, J., Thomson, N.M., Hypokalaemia-induced acute renal failure. Nephrol Dial Transplant 14:9 (1999), 2216–2218.
47. 47 Reungjui, S., Roncal, C.A., Sato, W., et al. Hypokalemic nephropathy is associated with impaired angiogenesis. J Am Soc Nephrol 19:1 (2008), 125–134.
48. 48 Chang, A.R., Sang, Y., Leddy, J., et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 67:6 (2016), 1181–1188.
49. 49 Weir, M.R., Bakris, G.L., Bushinsky, D.A., et al., OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372:3 (2015), 211–221.
50. 50 Packham, D.K., Rasmussen, H.S., Lavin, P.T., et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372:3 (2015), 222–231.
51. 51 Lepage, L., Dufour, A.C., Doiron, J., et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol 10:12 (2015), 2136–2142.
52. 52 Einhorn, L.M., Zhan, M., Hsu, V.D., et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169:12 (2009), 1156–1162.